The Phase 3 PSMAddition study tested whether adding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to standard treatment improves outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients received either standard therapy with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI), or the same treatment plus up to six cycles of Pluvicto.
The triplet therapy significantly improved radiographic progression-free survival (rPFS), reducing the risk of disease progression compared to standard care alone. Importantly, pain levels and the time to first symptomatic skeletal event or death were similar between the two groups.
Although patients receiving Pluvicto experienced a small, temporary drop in quality of life during the first 36 weeks, their scores recovered after treatment ended. Overall, the added therapy improved cancer control without causing long-term harm to quality of life.